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Nonsteroidal anti-inflammatory drugs (NSAIDs) have been reported to reduce the risk and mortality of colorectal cancer (CRC) by
inhibiting the activity of cyclooxygenase (COX). The present studies were directed to determine whether selective COX-2 inhibition
reduces CRC tumour cell proliferation and invasion/migration, and the possible cellular and molecular mechanisms involved. The MC-
26 cells are a highly invasive mouse CRC cell line expressing COX-2 protein. NS-398 (100mM), a highly selective COX-2 inhibitor,
decreased cell proliferation by B35% of control, as determined using [
3H]-thymidine incorporation. This reduction in cell
proliferation was associated with decreased expression of cyclin D1 and proliferating cell nuclear antigen (PCNA). Furthermore, NS-
398 inhibited cell invasion/migration through Matrigel extracellular matrix components at 24h by B60%. The addition of exogenous
prostaglandin E2 partially attenuated the inhibition of cell invasion by 10mM NS-398, but failed to reverse the effect of 100mM NS-398.
Matrix metalloproteinases-2 (MMP-2) and -9 (MMP-9) are two enzymes that facilitate cell invasion/migration by degrading the
extracellular matrix. In the presence of 100mM NS-398, Western blot hybridisation analysis and zymography demonstrated that both
MMP-2 and MMP-9 protein levels and enzyme activity were decreased by B25–30%. In separate studies, NS-398 also inhibited
tumour growth in vivo and retarded the formation of liver metastasis. The results of these studies indicate that the expression and
activity of COX-2 appear to be associated with both the proliferative and invasive properties of CRC. Cyclooxygenase-2 inhibition
suppresses tumour cell growth and invasion/migration, and retards liver metastasis in a mouse colon cancer model, via multiple
cellular and molecular mechanisms.
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Despite significant improvements in its prognosis due to advances
in diagnosis and therapy modalities, colorectal cancer (CRC)
remains second only to lung cancer as a cause of death from
malignant disease in the United States (Landis et al, 1998; Brenner,
2002; Singh et al, 2002). Epidemiological studies have demon-
strated a 40–50% reduction in mortality from CRC in individuals
taking nonsteroidal anti-inflammatory drugs (NSAIDs) (Martinez
et al, 1995; Ritland et al, 1999; Smalley et al, 1999; Garcia-
Rodriguez and Huerta-Alvarez, 2001). These agents appear to
reduce the risk of CRC by inhibiting cyclooxygenase (COX), also
known as prostaglandin G/H synthase (PGHS), a key enzyme
involved in the conversion of arachidonic acid to tissue-specific
prostaglandins. Two COX isoforms of cyclooxygenase (COX-1 and
COX-2) have been identified, and both isoenzymes are regulated in
a different manner and exhibit distinctive functional differences.
Cyclooxygenase-1 is expressed constitutively in many cell types,
whereas COX-2 is a primary response gene whose expression may
be induced by trauma, growth factors, tumour promoters and
cytokines (Taketo, 1998a,b; Dannenberg and Zakim, 1999;
Williams et al, 1999). Cyclooxygenase-2 was first discovered as
an oncogene-responsive isoenzyme, and increased COX-2 expres-
sion has been found in up to 85% of colorectal adenocarcinomas,
while it is undetectable in normal intestinal mucosa (Giardiello
et al, 1995; Kargman et al, 1995).
Nonselective COX inhibitors, which inhibit both isoforms, have
been reported to prevent tumorigenesis (Peura, 2002; Schwartz
et al, 2002). However, the use of nonselective COX inhibitors is
often associated with gastrointerestinal (GI) adverse events,
whereas COX-2 selective inhibitors are thought to exert anti-
inflammatory and their antineoplastic properties with diminished
toxicity (Hirata et al, 1997; Wolfe, 1998; Wolfe et al, 1999;
Lichtenstein and Wolfe, 2000). NS-398, N-[2-(cyclohexyloxy)-4-
nitrophenyl]-methanesulphonamide, is a sulphonamide derivative
that inhibits COX-2 specifically, with an IC50 of 30nM. This agent
does not affect COX-1 activity at concentrations exceeding 100mM,
and it inhibits COX-1 prostanoid production only minimally, even
at a dose exceeding 200mgkg
 1 (Futaki et al, 1994; Gierse et al,
1995). NS-398 can inhibit either chemically induced tumorigenesis
in the colon or human cancer xenograft in nude mice (Yoshimi
et al, 1997, 1999; Sawaoka et al, 1998).
NASIDs appear to exert their beneficial effects via multiple
mechanisms in cancer chemoprevention. It has been generally
assumed that the antiproliferative effects of NASIDs are dependent
upon inhibition of COX activity and prostaglandin synthesis. The
effects of COX-2 inhibitors on colonic carcinogenesis, cell cycle
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scontrol, differentiation, angiogenesis and apoptosis in cancer
chemopreventation have been described in numerous studies
(Tsujii and DuBois, 1995; Tsujii et al, 1998). Relatively little
attention has been given to COX with relation to tumour cell
invasive potential and metastasis. We have recently reported that
the COX-2 selective inhibitor rofecoxib decreased cell growth by
several mechanisms and decreased the metastatic potential of CRC
in the mouse (Yao et al, 2003). The mechanisms by which selective
COX-2 inhibition inhibits metastasis have not been determined.
The present studies were designed to extend our previous studies
to determine whether selective COX-2 inhibition with NS-398
likewise reduces CRC tumour cell proliferation and invasion/
migration, and to elucidate the possible cellular and molecular
mechanisms involved. The results of these studies indicate that the
expression and activity of COX-2 appears to be associated with
both the proliferative and invasive properties of CRC. Cycloox-
ygenase-2 inhibition significantly inhibits CRC growth and
invasion/migration, and retards the formation of liver metastasis
by multiple cellular and molecular mechanisms.
MATERIALS AND METHODS
Cell culture
The transplantable mouse CRC cell line MC-26 (Singh et al, 1986;
Walker et al, 1986) was obtained from Dr KK Tanabe (Massachu-
setts General Hospital, Boston, MA, USA). MC-26 cells were
maintained in Dulbecco’s modified Eagle’s medium (DMEM; Life
Technologies, Inc, Gaithersburg, MD, USA) supplemented with
10% foetal calf serum plus antibiotics at 371C in a humidified
atmosphere of 95% air/5% CO2.
Cell proliferation
Cell proliferation was determined by DNA synthesis, and then
confirmed by cell number counting. Cells (10
4ml
 1) were seeded
onto 12-well plates for 24h, followed by the addition of different
concentrations of NS-398 (Cayman chemical, Ann Arbor, MI,
USA). NS-398 was dissolved in dimethylsulphoxide (DMSO) as a
stock solution. DNA synthesis was estimated by [
3H]-thymidine
incorporation into cellular DNA. [
3H]-thymidine 1mCiml
 1 (New
England Nuclear Products, Boston, MA, USA) was added and
allowed to label for 6h at 371C. Cells were washed  3 with cold
phosphate-buffered saline (PBS), and cold 10% trichloroacetic acid
(TCA) was added to cells for 30min at 41C. Cells were washed
again  3 with cold PBS, after which they were lysed in 0.1 N
NaOH/10% SDS and radioactivity measured in a liquid scintilla-
tion counter. Data were expressed as the percentage of control, in
order to reduce variation among separate experiments. Protein
synthesis was measured by a BCA protein assay kit (Pierce
chemical, Rockford, IL, USA), according to the protocol provided
by the manufacturer. For cell number counting, cells (10
4ml
 1)
were seeded onto six-well plates for 24h, followed by the addition
of different concentrations of NS-398. Cells were harvested and
then cell numbers were manually counted under the microscope.
Prostaglandin E2 assay
Prostaglandin E2 (PGE2), the major metabolite of arachidonic acid
metabolism, was measured by ELISA (Cayman Chemical, Ann
Arbor, MI, USA) with conditional cell culture medium, according
to the protocol provided by the manufacturer. Measurements were
made in triplicate in separate experiments.
Cell invasion/migration assay
A membrane invasion culture system (Collaborative Biomedical
Products, Bedford, MA, USA) was used to quantify cell invasion
and migration, as described previously (Rozic et al, 2001). The
upper surface of the polycarbonate filter with 8-mm pores was
coated with Matrigel, and placed between the upper and lower well
plates of the membrane invasion system. Serum-free Swiss 3T3
fibroblast conditional medium (CM) was prepared by incubation
of these cells for 24h. This medium was used as a chemoattractant
in the lower chamber. After reaching 60–70% subconfluence, cells
were harvested by trypsinisation and suspended in DMEM, and
harvested cells (10000ml
 1) were seeded into the upper chambers.
Cells were cultured in the presence of various concentrations of
NS-398 alone, or in combination with exogenous PGE2 (Cayman
Chemical, Ann Arbor, MI, USA) for 24h. At the end of 24
incubation at 371C, the cells in the upper surface of the Matrigel-
coated filter were mechanically removed, the filters fixed with
methanol, stained with haematoxylin and eosin, and the cells on
the lower surface were counted manually.
Gelatin zymography
Gelatin zymography was performed using CM harvested from MC-
26 cells under various conditions as described (Nomura et al, 1995;
Liabakk et al, 1996). Conditional medium was collected and
concentrated six-fold using Centricon 10 filter (Amicon), and then
subjected to 10% SDS–PAGE with 1mgml
 1 gelatin incorporated
into the gel mixture. Following electrophoresis at 41C, the gel was
soaked in 2.5% Triton X-100 to remove the SDS, rinsed in H2O
 3, and then transferred to a developing buffer (50mM Tris-HCL
pH 7.5, 5mM CaCl2, 200mM NaCl) at 371C overnight. Gels were
stained with Coomassie blue for 2–3h and then destained with
30% methanol and 10% acetic acid. The unstained bands (digested
gelatin) correspond to the presence of matrix metalloproteinase
(MMP) proteolytic activity.
Animal experimental design
Male BALB/c mice, 6-week old, were obtained from Taconic
(Germantown, NY, USA). The mouse colon cancer model was
established as described previously (Yao et al, 2002). MC-26 cells
were harvested from subconfluent cultures by exposure to trypsin-
EDTA (Life Technologies, Inc, Gaithersburg, MD, USA) for 3min,
centrifugation at 300g for 15min at room temperature, and then
resuspension in serum-free DMEM or Hank’s balanced salt
solution (Life Technologies, Inc, Gaithersburg, MD, USA), to yield
a final concentration of 10
5cellsml
 1. Using a 27-gauge needle and
a 1-ml syringe, 100ml of tumour cell suspension was injected
subcutaneously into the flank of the mice. All animal studies were
conducted using a protocol approved by the Institutional Animal
Care and Use Committee of Boston University Medical Center.
NS-398, dissolved in DMSO, was administered by oral gavage
once daily. Mice were randomly divided into three groups (10
animals/group) on day 0 after tumour cell implantation: vehicle
(DMSO), NS-398 1mgkg
 1, NS-398 10mgkg
 1. Starting on day 7,
subcutaneous tumour size was determined by measuring the
longest and shortest diameters of the tumour at 2–3 days intervals.
Tumour volume (mm
3) was calculated by a standard formula:
volume¼(the shortest diameter)
2 (the longest diameter) 0.5.
Tumour weight was also measured on day 18 after tumours were
removed from the killed mice. Tumour tissue was frozen in liquid
nitrogen and stored at  701C.
For the liver metastasis tumour model, 2 10
4cellsml
 1 MC-26
cells were injected into the subsplenic capsule of 6–10-week-old
BALB/c mice under intraperitoneal anaesthesia using pentobarbital
(65mgkg
 1 body weight) on day 0. After full recovery from
surgery, mice were randomly divided into three groups (n¼12 per
group): vehicle (DMSO), NS-398 10mgkg
 1, and NS-398
100mgkg
 1. Mice were administered with NS-398 once a day by
gavage, starting on day 1. Six mice in each group were killed on
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sday 10 and another six mice on day 14. The incident rates of liver
metastases were recorded.
Western blot hybridisation
Mouse cyclin D1 and COX-2 monoclonal antibodies were
purchased from BD transduction laboratories (Lexington, KY,
USA). To extract the protein, MC 26 cells were harvested and lysed
in RIPA buffer (PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1%
SDS, 100ngml
 1 PMSF, 66ngml
 1 aprotinin). To extract protein
from tissues, 0.1g tumour tissue was put in 2.0ml of cold protein
extract buffer (RIPA buffer) and homogenised for 1min with
Polytron-Aggregate (Kinmatica, Luzern, Switzerland). After the
removal of cellular debris by centrifugation, total protein extracted
from cells or tissues was determined by BCA protein assay
(Pierce chemical, Rockford, IL, USA). Protein was mixed with
gel-loading buffer (50mM Tris pH 6.8, 2% SDS, 10% glycerol,
2% 2-mercaptoethanol, 0.1% bromphenol blue) and heated
for 10min at 1001C. Samples containing 5–20mg protein
were loaded onto 10–12% SDS–PAGE gel, and then electrophor-
etically transferred to polyvinylidene difluoride membrane
in a transfer buffer (25mM Tris, 190mM glycine, 20% methanol).
The blots were blocked with 7% dry milk for 1h at room
temperature and incubated with the first antibody overnight. The
blots were then washed three times for 15min each in Tris-
buffered saline containing 0.05% tween-20. The blots were further
incubated with the anti-mouse IgG antibody (Sigma Chemical Co.,
St Louis, MO, USA) for 1h at room temperature. After washing
three times, blots were incubated with luminous ECL reagent
(Pierce chemical, Rockford, IL, USA) for 10–120s and exposed to
Kodak X-ray film. Protein bands were identified by protein size
and positive control provided by BD transduction laboratories
(Lexington, KY, USA). The amount of protein expression was
quantified by densitometry.
Immunohistochemistry
Proliferating cell nuclear antigen (PCNA) monocolonal antibodies
were purchased from BD transduction laboratories. Paraffin-
embedded specimens were deparaffinised and incubated with
PCNA antibody for 2h at 371C. The specimens were then
incubated with secondary antibody, anti-mouse IgG, for 1h at
371C, and stained by the avidin–biotin peroxide complex (ABC)
method using an ABC staining system (Santa Cruz Biotech, Santa
Cruz, CA, USA). They were visualised by 3,30-diaminobenzidine
(DAB) and counterstained with haematoxylin. To confirm the
specificity of the mouse PCNA antibody, human tonsil specimens
was used as a positive control. The PCNA index was evaluated by
counting the number of PCNA-positive-staining cells per 500
tumour cells: PCNA index¼(numbers of PCNA-positive-staining
cells/500 cells counted) 100%.
Statistical analysis
One-way ANOVA was performed for comparing the tumour
volume and weight, PCNA index and densitometric values of
Western blot bands among different animal groups, followed by
Tukey’s procedure for pairwise comparison. Incident rates of liver
metastatsis were analysed using the Fisher’s exact test. Statistical
significance was assigned if Po0.05.
RESULTS
COX-2 expression and prostaglandin levels following
treatment with NS-398
Although NS-398 has been shown to decrease the activity of COX-2
in some CRC cell lines, no significant changes in COX-2 protein
expression were detected in mouse colorectal adenocarcinoma cell
line MC-26 after treatment with NS-398 (1, 10 and 100mM) for 24h
(Figure 1A). In contrast, concentration-dependent decreases in
PGE2, a major product of the arachidonic acid pathway, were
demonstrated after 24h of incubation with NS-398. Compared
with vehicle incubation (2.0870.35ngmg
 1 total protein), PGE2
content in cells treated with 1, 10 and 100mM NS-398 were
diminished by approximately 50% (1.0070.20ngmg
 1), 80%
(0.4870.03ngmg
 1) and 90% (0.2570.07ngmg
 1), respectively
(Figure 1B).
Cell proliferation and tumour growth in vivo
The addition of NS-398 to MC-26 cells led to a concentration-
dependent decrease in [
3H]-thymidine incorporation. NS-398 1, 10
and 100mM decreased cell proliferation to 84.3, 57.2 and 34.6% at
72h, respectively, compared to cells incubated in the absence of
NS-398 (Figure 2A). These results had been confirmed by cell
number counting, showing that significant cell number reduction
occurred at 72h after NS-398 treatment (Figure 2B). Figures 3A
and B depict the effects of NS-398 on subcutaneous tumour
volume and tumour weight at the end of the study (day 18).
Although low-dose (1mgkg
 1) NS-398 did not affect subcutaneous
tumour growth compared with control animals (tumour volume:
1208.27223.6 vs 1220.27224.0mm
3; tumour weight: 0.39270.08
vs 0.38470.07g, P40.05), high-dose (10mgkg
 1) NS-398 sig-
nificantly decreased subcutaneous tumour growth (tumour
volume: 843.37226.8mm
3; tumour weight: 0.21870.05g, both
Po0.05). As shown in Figure 3C, no significant changes in body
weight were detected among these groups.
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Figure 1 (A) Western blot of COX-2 protein and (B) quantification of
its product, PGE2. MC-26 cells were maintained in DMEM media
supplemented with 10% foetal calf serum. Cells (100000ml
 1) were
seeded for 24h, followed by the addition of different concentrations of NS-
398. Total protein was extracted and Western blot hybridisation
performed for COX-2 expression. PGE2 was measured using ELISA, as
described in Materials and methods section. Measurements were made in
triplicate in three separate experiments, and data are depicted as the
mean7standard error (s.e.). *Po0.01, compared to control (vehicle).
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sTo further assess the inhibitory effects of NS-398 on cell
proliferation and tumour growth, we measured cyclin D1 and
PCNA levels using Western blot hybridisation and immunohis-
tochemistry. Cyclin D1 is one of the key proteins involved in cell
cycle regulation in normal cells (Hunter and Pines, 1994; Sherr,
1996). In the G1 (resting) phase of the cell cycle, cyclin D1 along
with its cyclin-dependent kinase (CDK) partner, is responsible for
transition to the S (DNA synthesis) phase. Overexpression of
cyclin D1 releases a cell from its normal control and causes
transformation to a malignant phenotype (Motokura and Arnold,
1993; Bartkova et al, 1994; Arber et al, 1996; Sutter et al, 1997).
PCNA functions as an auxiliary protein to DNA polymerase-g and
as a co-factor in DNA synthesis. The determination of PCNA
represents one of the most reliable methods for evaluating
proliferation in cells and tissues (Prosperi, 1997). In the present
study, consistent with the cell proliferation and tumour growth,
cyclin D1 levels (normalised to actin protein) were decreased after
MC-26 cells were incubated in the presence of NS-398 (100mM) for
48 and 72h (Figure 4A). The PCNA index was also significantly
decreased in mice treated with NS-398 10mgkg
 1, compared with
mice administered vehicle only (27.073.2 vs 10.872.6%, Po0.01)
(Figure 4B,C).
Effects of NS-398 on cell invasion potential and liver
metastasis
To quantify cell invasion, we employed a Matrigel invasion
chamber assay. Matrigel is a solubilised basement membrane
preparation containing extracellular components such as laminin,
collagen type IV, heparin sulphate proteoglycan, and growth
factors such as TGF and basic FGF. The layer of Matrigel Matrix
simulates a reconstituted basement membrane in vitro. To perform
these experiments, an invasion assay was established, that included
upper and lower chambers separated by a filter, onto which the
cells are trapped and can be counted. The bottom of the upper
chamber was coated with Matrigel. Highly invasive cells are able to
degrade the extracellular matrix components and migrate through
the layer of Matrigel to the other side of filter by activating various
proteinases. The lower chamber was filled with serum-free
conditioned 3T3 fibroblast medium, to act as a chemoattractant.
Cells pretreated with NS-398 or vehicle were loaded into the upper
chamber, and, following a 24-h incubation period, the number of
cells attached to the filters below the Matrigel layer was counted.
As shown in Figure 5, 1–100mM NS-398 inhibited cell invasion/
migration through the Matrigel extracellular matrix components at
24h in a concentration-dependent reduction, with maximum
inhibition of 78% of control (13.075.4 vs 58.5713.1 cells per
microscopic field under control conditions, Po0.01). Since cell
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Figure 2 Effect of NS-398 on cellular proliferation. (A) DNA synthesis
was measured by [
3H]-thymidine incorporation into cellular DNA. [
3H]-
thymidine 1mCiml
 1 was added and allowed to label for 6h at 371C. Cell
lysates were analysed in a liquid scintillation counter. Data are expressed as
the percentage of control (vehicle)7s.e. (B) Cells (10
4ml
 1) were seeded
onto six-well plates for 24h, followed by the addition of different
concentrations of NS-398. Cells were harvested and then cell numbers
were manually counted under the microscope. *Po0.05, **Po0.01,
compared to control (vehicle).
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Figure 3 (A) Tumour growth (volume) in vivo over time and (B)
tumour weight and (C) body weight after excision on day 18. Tumour
volume (mm
3) was determined by measuring the longest and shortest
diameter of the tumour, and was calculated by a standard formula:
volume¼(the shortest diameter)
2 (the longest diameter) 0.5. Tumour
weight was measured on day 18, after excision from the killed mice. Data
are expressed as the mean7s.e. *Po0.05, compared to control (vehicle).
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snumber did not significantly decrease at 24h after NS-398
treatment (Figure 5), the inhibitory effect of NS-398 at 24h may
occur as a result of reduced cell-invasive capacity rather than a
reduction in cell number. The addition of exogenous PGE2
partially attenuated the inhibition of cell invasion produced by
10mM NS-398, but not in cells treated with 100mM NS-398.
To further explore the molecular mechanisms by which NS-398
decreased the invasive capacity of MC-26 cells, we measured MMP
concentrations. Metalloproteinases consist of a family of nine or
more highly homologous Zn
2þ peptidases that collectively cleave
the constituents of extracellular matrix and facilitate tumour cell
invasion and migration. Metalloproteinases play an important role
in tumour invasion and metastasis (Curran and Murray, 2000;
Nelson et al, 2000). Within the MMP family, MMP-2 and -9, also
called gelatinases or type-IV collagenases, have been implicated to
play a significant proteolytic role in CRC invasion and metastasis.
As seen in Figure 6, after the incubation of MC-26 cells with 100mM
NS-398 for 24h, both protein expression (Western blot) and
enzyme activity (zymography) of MMP-2 and -9 enzymes were
decreased by approximately 25–30% (Po0.05).
The liver is the major target organ for CRC metastasis. We
established a CRC liver metastasis model by injecting tumour cells
into the splenic subcapsule. Visible metastatic lesions in the liver
were detected by day 7 after cell inoculation. On day 10, the
incidence of liver metastasis in the NS-398-treated group
(100mgkg
 1day
 1) was significantly lesser than that in control
group (one out of six vs five out of six, Po0.05). However, on day
14, liver metastasis occurred in 100% (six out of six) in control and
83.33% (five out of six) in the NS-398-treated group (NS-398
100mgkg
 1day
 1, P40.05). These results indicate that NS-398
delayed, but did not prevent, liver metastasis (Figure 7).
DISCUSSION
COX-2 overexpression has been demonstrated in B85% of cases of
primary CRC. Overexpression of COX-2 appears to alter the
phenotype of intestinal epithelial cells and increases their
carcinogenic potential. A number of epidemiological studies have
shown that the prolonged use of aspirin and other nonsteroidal
anti-inflammatory drugs (NSAIDs) can reduce the relative risk of
CRC (Giovannucci et al, 1994; Smalley et al, 1999). For example, a
recent population-based survey in 4100000 individuals 65 years
of age and older found that the long-term use of NSAIDs
diminished the risk of CRC by B50% (Giovannucci et al, 1994;
Smalley et al, 1999). Another large population-based survey
reported that the use of NSAIDs significantly reduced the risk of
both gastric and oesophageal carcinoma (Farrow et al, 1998).
Although the precise mechanisms by which NSAIDs, and COX-2
selective inhibitors in particular, modulate tumour growth have
not been elucidated, it appears that cell cycle arrest and apoptosis
may play a critical role (Chang and Weng, 2001; Grosch et al, 2001;
Cheng et al, 2002; Joe et al, 2002; Kundu et al, 2002; Toyoshima
et al, 2002). Alternatively, Sawaoka et al (1998) and Tsujii et al
(Tsujii and DuBois, 1995; Sawaoka et al, 1998; Tsujii et al, 1998)
have suggested that a decrease in angiogenesis may account for the
inhibitory properties of COX-2 selective NSAIDs on tumour
growth. Early studies demonstrated that sulindac was effective in
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Figure 4 (A) Effect of NS-398 on cyclin D1 protein expression in cells
over time, (B) representative photomicrograph of PCNA staining of
tumour tissue, and (C) PCNA index. Cyclin D1 protein was detected by
Western blot hybridisation, and PCNA was determined by immunohis-
tochemistry. PCNA index was calculated by counting the number of
PCNA-positive-staining cells per 500 tumour cells: PCNA in-
dex¼(numbers of PCNA-positive cells/500 cells counted) 100.
*Po0.05, compared to control.
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Figure 5 Effect of NS-398 on cell invasion/migration in vitro. Cell
invasion/migration assay was performed using the Matrigel invasive
chamber system, as described in Materials and methods section. (A)
Number of cells on the undersurface of filters after 24h in the presence of
NS-398 alone, or in combination with PGE2 100nM.( B) Representative
photomicrograph of cells on the undersurface of filters after 24h in the
presence of NS-398 100mM or vehicle. *Po0.05, **Po 0.01, compared to
NS-398 0mM.
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sreducing the number of colonic polyps in individuals with familial
adenomatous polyposis (FAP), presumably by decreasing the
activity of COX (Waddell and Loughry, 1983). Selective COX-2
inhibitors share the antitumour properties of nonselective NSAIDs
like sulindac, but are associated with far fewer adverse GI events
(Wolfe, 1998; Wolfe et al, 1999). Cyclooxygenase-2 selective
inhibitors have been shown to inhibit the growth of tumour cells
in vitro (Sheng et al, 1997). They also reduce the development of
precancerous adenomatous polyps in the Apc
D716 knockout mouse,
a model of human hereditary familial adenomatous polyposis, and
in the azoxymethane rat model, which produces benign and
malignant colorectal adenomatous polyps analogous to nonher-
editary spontaneous development of colorectal adenocarcinoma
(Williamson et al, 1978; Oshima et al, 1996; Singh et al, 2000).
In December 1999, the US Food and Drug Administration
approved the use of the COX-2 selective NSAID celecoxib in
individuals with FAP, both for the regression and reduction of
polyps. While FAP serves as an excellent model for CRC, it is a rare
condition, accounting for o1% of all cases. The present therapy
for the treatment of advanced CRC is not only quite toxic, but also
largely ineffective. A previous in vitro study using cell lines of CRC
origin by Tsujii et al (1997) suggested that COX-2 inhibition may
be beneficial in preventing the expression of genes associated with
metastatic progression. Furthermore, a recent study by Tomozawa
et al (1999) demonstrated that the COX-2 selective inhibitor JTE-
522 might decrease the rate of haematogenous metastasis of CRC.
Many NSAIDs have been found to inhibit cell division and alter
cell cycle distribution in culture colon cancer cells (Xu et al, 1999;
Grosch et al, 2001; Kundu et al, 2002). In the present study, cell
proliferation was inhibited by NS-398, a COX-2 selective inhibitor,
in a concentration-dependent manner, with a maximum inhibition
of 34.6% of control values. In the subcutaneous colon tumour
models, mice treated with 10mgkg
 1 NS-398 displayed approxi-
mately 50–70% of the tumour burden compared to control
animals. To confirm the antiproliferative effect of NS-398, we
examined two proliferation-related molecules: cyclin D1 and
PCNA. Previous studies have demonstrated that cyclin D1 is
increased in adenomatous polyps and in both sporadic and
familial forms of CRC (Motokura and Arnold, 1993; Bartkova et al,
1994; Arber et al, 1996; Sutter et al, 1997). The synthesis and
expression of PCNA are enhanced in proliferating cells, including
those that are tumour-derived. Consistent with the cell prolifera-
tion and animal tumour growth data observed, cyclin D1 and
PCNA index were significantly decreased by NS-398 both in vitro
and in vivo.
Tumour metastasis is a complex multifactorial and multistep
biological process. Tumour cell invasive potential, host micro-
enviroment and interactions between host and tumour cells are
among the factors influencing the establishment and development
of metastatic lesions (Woodhouse et al, 1997). Cyclooxygenase-2
overexpression has been associated with increased adhesion to the
extracellular matrix and the inhibition of apoptosis (Tsujii and
DuBois, 1995). Cyclooxygenase-2 also leads to alterations in the
invasive potential of CRC cells (Tsujii et al, 1997). Metastatic CRC
cells from liver and primary CRC tissue exhibit much higher levels
of COX-2 than the corresponding adjacent normal mucosa from
the same patient. Among patients with relatively high COX-2
expression in the primary tumour, almost all were found to exhibit
even higher levels of COX-2 in their hepatic metastases (Chen et al,
2001). The precise mechanism underlining the roles of COX-2 in
the metastasis process is unknown. It has been reported that
proteolysis of the extracellular matrix and angiogenesis are
involved in the process (Tsujii and DuBois, 1995; Tsujii et al,
1997, 1998). One of the major steps in the process of cancer cell
invasion is proteolysis of the extracellular matrix, especially the
basement membrane, including fibronectin, laminin, type IV
collagen and proteoglycans (Coussens et al, 2002; Vihinen and
Kahari, 2002). Using reconstituted basement membrane Matrigel
in vitro, we found that NS-398 significantly inhibited the capacity
of cell invasion and migration through the extracellular matrix by
inactivating the activities of MMP-2 and -9. Metalloproteinase
inhibition could thus account for one of the molecular mechanisms
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Figure 6 (A) Activity of MMP-2 and -9 in NS-398-treated cells using
gelatin zymography and (B) protein expression of MMP-2 and -9 using
Western blot hybridisation, as described in Materials and methods section.
MC-26 cells were cultured without and with increasing concentrations of
NS-398 for 24h.
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Figure 7 Effect of NS-398 on liver metastasis. A mouse CRC liver
metastasis model was established by splenic subcapsule tumour cell
injection. Mice were administered vehicle or NS-398 (10 or 100mgkg
 1)
once daily by gavage. On days 10 and 14, the incidence of liver metastasis
was recorded. *Po0.05, compared to control.
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sinvolved in mediating the anti-invasive properties of NS-398. We
also found that the addition of exogenous PGE2 partially
attenuated the inhibition effect of NS-398 at 10mM, but not with
100mM, indicating that the invasion/migration-inhibitory effects of
NS-398 might also be modulated through COX-independent
pathways.
To determine whether NS-398 possessed any inhibitory effects
on the development of liver metastasis, we utilised an animal
model that generates metastasis by the injection of MC-26 cells
into the splenic subcapsule. Although we did observe a decrease in
subcutaneous tumour growth in response to the administration of
10mgkg
 1 NS-398 (Figure 3), this same dose had no significant
effect on liver metastasis. When administered by gavage at a daily
dose of 100mgkg
 1, however, the rate of metastasis was
significantly diminished (Figure 7). The mechanisms accounting
for the higher dose requirements are not known, but may be due,
at least in part, to the more abundant blood supply in the spleen
compared to the subcutaneous space or alternatively to differences
in the cellular and molecular mechanisms responsible for
mediating the effects of COX-2 inhibition on tumour growth and
metastasis. NS-398 at the 100mgkg
 1 dose decreased the
development of liver metastasis on day 10, but not on day 14,
indicating that NS-398 appears to retard, but not prevent, the early
formation of liver metastasis using this model.
In conclusion, the expression and activity of COX-2 appears to
be associated with the proliferative and invasive properties of CRC.
Cyclooxygenase inhibition suppresses tumour cell growth and
invasion, and retards the formation of liver metastasis in a mouse
CRC model by multiple cellular and molecular mechanisms.
Further studies are warranted to evaluate the possibility that COX-
2 inhibition be considered as part of the treatment regimen for
advanced CRC.
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